While combining the three mRNAs’ expression did not increase the prediction of clinically significant PCa (AUC 0.74 vs. AUC 0.82 of PSMA and AUC 0.75 of PCA3 biomarker), the panel comprising three mRNA transcripts along with sPD-L1 demonstrates significant enhancement in diagnostic properties compared to mRNA transcripts without sPD-L1, with an AUC of 0.94, accuracy of 0.96, sensitivity of 0.83 and specificity of 100%. The gene discussed is SPDL1; the disease is posterior cortical atrophy.